Evidence map›Paper›PMID 36905562›Full record

Observational studyJournal of thrombosis and thrombolysis2023

Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy.

M Berteotti, A M Gori, B Giusti, A Fortini, G Grossi, N Ciardetti, A Migliorini, E Lotti, R Valenti, C Di Mario and 2 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of thrombosis and thrombolysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

M BerteottiDepartment of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy. martina.berteotti@unifi.it.ORCID http://orcid.org/0000-0001-8281-4734
A M GoriDepartment of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy.
B GiustiDepartment of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy.
A FortiniDepartment of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy.
G GrossiDivision of Interventional Cardiology, Cardiothoracovascular Department, Careggi University Hospital, Florence, Italy.
N CiardettiDivision of Interventional Cardiology, Cardiothoracovascular Department, Careggi University Hospital, Florence, Italy.
A MiglioriniDivision of Interventional Cardiology, Cardiothoracovascular Department, Careggi University Hospital, Florence, Italy.
E LottiThrombosis Center, Careggi University Hospital, Florence, Italy.
R ValentiDivision of Interventional Cardiology, Cardiothoracovascular Department, Careggi University Hospital, Florence, Italy.
C Di MarioDepartment of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy.
N MarchionniDepartment of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy.
R MarcucciDepartment of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy.
University of Florence · ITAzienda Ospedaliero-Universitaria Careggi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High platelet reactivity (HPR) on clopidogrel is an established thrombotic risk factor after percutaneous coronary intervention (PCI). The introduction of more potent antiplatelet drugs has partially surpassed this issue. However, in the setting of concomitant atrial fibrillation (AF) and PCI clopidogrel is still the most adopted P2Y

Indexed as

Atrial FibrillationPercutaneous Coronary InterventionClopidogrelCytochrome P-450 CYP2C19Fibrinolytic AgentsHemorrhageHumansPlatelet Aggregation InhibitorsClopidogrelCytochrome P-450 CYP2C19Fibrinolytic AgentsPlatelet Aggregation InhibitorsAntiplatelet therapyCYP2C19 polymorphismOral anticoagulantPlatelet reactivityTriple antithrombotic therapy

Identifiers

PMID36905562
PMCPMC10147742
OpenAlexW4323921084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.